The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed/refractory multiple myeloma.
|Articles|December 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 12
- Volume 5
- Issue 12
AHCPR to Fund Analysis of the Impact of Managed Care's Growth
WASHINGTON--The Agency for Health Care Policy and Research (AHCPR) has funded a new analysis of the impact of the recent growth and concentration of HMOs on employers, health-insurance coverage decisions, health care premiums, and employees' health insurance choices. Jack Hadley, MD, of Georgetown University, will lead the $307,437, year-long project.
Advertisement
WASHINGTON--The Agency for Health Care Policy and Research (AHCPR)has funded a new analysis of the impact of the recent growth andconcentration of HMOs on employers, health-insurance coveragedecisions, health care premiums, and employees' health insurancechoices. Jack Hadley, MD, of Georgetown University, will leadthe $307,437, year-long project.
Articles in this issue
almost 30 years ago
Avon Funds Breast Cancer Awareness Program for Orthodox Jewish Womenalmost 30 years ago
Friends of Cancer Research Campaignalmost 30 years ago
Four Cancer Chemoprevention Trials Seek Subjectsalmost 30 years ago
Overall US Cancer Mortality Rate Falls for the First Timealmost 30 years ago
Four Scenarios Describe Impact of Cancer Research in 2015almost 30 years ago
New Edition of NABCO Breast Cancer Resource List Is Now Availablealmost 30 years ago
Changes in Congressional Committee Chairmen Could Impact Oncologistsalmost 30 years ago
Growth Factor in Elderly ALL Patients Improves OutcomeAdvertisement
Related to this article
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 PERSEUS study.
Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma.
In the phase 2 IBEX trial, iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in patients with multiple myeloma.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
Acting on a HER2 Result and Navigating Access to Therapy
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5